文献速递核素与放射性配体治疗

α发射体间位-211At-砹代苄胍在PC12嗜铬细胞瘤模型中的抗肿瘤效应

Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-01-19

研究在PC12嗜铬细胞瘤荷瘤小鼠中评估α发射体间位-211At-砹代苄胍(211At-MABG)的抑瘤效果,荷瘤小鼠静脉注射0.28至5.55 MBq的211At-MABG后观察8周肿瘤体积。结果显示治疗组前38天相对肿瘤生长显著低于对照组,第21天相对肿瘤体积对照组为509.2%±169.1%、0.56 MBq组为9.6%±5.5%(p<0.01),0.28、0.56和1.11 MBq组仅出现暂时性体重下降并于第10天恢复。作者认为211At-MABG可能成为治疗恶性嗜铬细胞瘤的有效药物。

要点

  • 211At-MABG治疗组前38天相对肿瘤生长显著低于对照组。
  • 第21天相对肿瘤体积对照组509.2%±169.1% vs 0.56 MBq组9.6%±5.5%(p<0.01)。
  • 0.28、0.56和1.11 MBq组仅暂时性体重下降,第10天恢复。

核心结论

  • 211At-MABG在小鼠嗜铬细胞瘤模型中表现出较强的缩小肿瘤体积的作用,且未出现体重下降。
  • 作者认为211At-MABG可能成为治疗恶性嗜铬细胞瘤的有效药物。

研究设计与样本

  • 研究使用大鼠嗜铬细胞瘤细胞系PC12荷瘤小鼠,评估211At-MABG的缩小肿瘤体积作用。
  • PC12荷瘤小鼠静脉注射211At-MABG,剂量为0.28、0.56、1.11、1.85、3.70和5.55 MBq,每组五只小鼠。
  • 给药后评估肿瘤体积8周;对照组十只小鼠接受磷酸盐缓冲液。

主要发现

  • 211At-MABG治疗组小鼠前38天相对肿瘤生长显著低于对照组。
  • 第21天相对肿瘤体积对照组为509.2%±169.1%,0.56 MBq组为9.6%±5.5%(p<0.01)。
  • 接受0.28、0.56和1.11 MBq 211At-MABG的小鼠仅出现暂时性体重下降,第10天体重恢复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Therapeutic options for patients with malignant pheochromocytoma are currently limited, and therefore new treatment approaches are being sought. Targeted radionuclide therapy provides tumor-specific systemic treatments. The β-emitting radiopharmaceutical meta-131I-iodo-benzylguanidine (131I-MIBG) provides limited survival benefits and has adverse effects. A new generation of radionuclides for therapy using α-particles including meta-211At-astato-benzylguanidine (211At-MABG) are expected to have strong therapeutic effects with minimal side effects. However, this possibility has not been evaluated in an animal model of pheochromocytoma. We aimed to evaluate the therapeutic effects of the α-emitter 211At-MABG in a pheochromocytoma model. METHODS: We evaluated tumor volume-reducing effects of 211At-MABG using rat pheochromocytoma cell line PC12 tumor-bearing mice. PC12 tumor-bearing mice received intravenous injections of 211At-MABG (0.28, 0.56, 1.11, 1.85, 3.70 and 5.55 MBq; five mice per group). Tumor volumes were evaluated for 8 weeks after 211At-MABG administration. The control group of ten mice received phosphate-buffered saline. RESULTS: The 211At-MABG-treated mice showed significantly lower relative tumor growth during the first 38 days than the control mice. The relative tumor volumes on day 21 were 509.2% ± 169.1% in the control mice and 9.6% ± 5.5% in the mice receiving 0.56 MBq (p < 0.01). In addition, the mice treated with 0.28, 0.56 and 1.11 MBq of 211At-MABG showed only a temporary weight reduction, with recovery in weight by day 10. CONCLUSION: 211At-MABG exhibited a strong tumor volume-reducing effect in a mouse model of pheochromocytoma without weight reduction. Therefore, 211At-MABG might be an effective therapeutic agent for the treatment of malignant pheochromocytoma.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ohshima Y, Sudo H, Watanabe S, et al. Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging. 2018. PMID: 29350258. doi:10.1007/s00259-017-3919-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。